Cargando…

Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater

Introduction: Ampulla of Vater tumors, neoplastic diseases located at the confluence of the common bile duct with the main pancreatic duct; represent 0.2% of all gastrointestinal cancers. Method: Retrospective study of all patients admitted in the Emergency Hospital of Bucharest Romania between Janu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaspar, B, Beuran, M, Paun, S, Ganescu, R, Hostiuc, S, Negoi, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786484/
https://www.ncbi.nlm.nih.gov/pubmed/24146684
_version_ 1782477745635196928
author Gaspar, B
Beuran, M
Paun, S
Ganescu, R
Hostiuc, S
Negoi, I
author_facet Gaspar, B
Beuran, M
Paun, S
Ganescu, R
Hostiuc, S
Negoi, I
author_sort Gaspar, B
collection PubMed
description Introduction: Ampulla of Vater tumors, neoplastic diseases located at the confluence of the common bile duct with the main pancreatic duct; represent 0.2% of all gastrointestinal cancers. Method: Retrospective study of all patients admitted in the Emergency Hospital of Bucharest Romania between January 2008 and January 2013, the only selection criterion used being a pathology report which describes an ampulla of Vater carcinoma. We have also performed a review of the medical literature up to 2013, using the PubMed/Medline, Proquest Hospital Collection, Science Direct, Cochrane Library and Web of Science databases. We have used different combinations of the following keywords: “ampulla of Vater", “carcinoma", “resection", reviewing the reference list of retrieved articles for further relevant studies. Results: Forty eight patients with ampulla of Vater carcinoma were identified, of whom 59.6% men, 71% from urban areas, and a mean age of 66 ± 13.3 years. Most patients were admitted for obstructive jaundice (49%), right upper quadrant abdominal pain (19%), nausea and loss of appetite in 13%, loss of weight (13%) and upper digestive obstruction in 6% of cases. All patients were evaluated with abdominal transparietal ultrasonography and double contrast, pancreatic protocol, Mutidetector Row Computed Tomography. The abdominal Magnetic Resonance Imaging was performed in 10 cases, upper gastrointestinal endoscopy in 9 cases, and Endoscopic Retrograde Cholangiopancreatography in 39 cases. According to the AJCC Cancer Staging 9% were into stage I, 47% into stage II, 40% into stage III and 4% into stage IV of the disease. The therapeutic approach was surgical for 44 patients and an endoscopic palliation with stent insertion in 4 cases. The surgical procedure was represented by Whipple pancreatoduodenectomy in 27 cases, pylorus preserving pancreatoduodenectomy in 15 cases and exploratory laparotomy in 2 cases. Early morbidity was represented by pancreatic leakage in 4 cases. Conclusions: There are clinical scenarios in which it is quite challenging to distinguish a primary ampullary adenocarcinoma based on a preoperative workup. Nevertheless, an aggressive approach should be performed, knowing the higher resectability rates and a five-year survival for these patients. Complete surgical resection should be performed in all medically fit patients, candidates for pancreatoduodenectomy, by a high volume, trained surgeon, able to offer a low morbidity and mortality.
format Online
Article
Text
id pubmed-3786484
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-37864842013-11-15 Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater Gaspar, B Beuran, M Paun, S Ganescu, R Hostiuc, S Negoi, I J Med Life Original Article Introduction: Ampulla of Vater tumors, neoplastic diseases located at the confluence of the common bile duct with the main pancreatic duct; represent 0.2% of all gastrointestinal cancers. Method: Retrospective study of all patients admitted in the Emergency Hospital of Bucharest Romania between January 2008 and January 2013, the only selection criterion used being a pathology report which describes an ampulla of Vater carcinoma. We have also performed a review of the medical literature up to 2013, using the PubMed/Medline, Proquest Hospital Collection, Science Direct, Cochrane Library and Web of Science databases. We have used different combinations of the following keywords: “ampulla of Vater", “carcinoma", “resection", reviewing the reference list of retrieved articles for further relevant studies. Results: Forty eight patients with ampulla of Vater carcinoma were identified, of whom 59.6% men, 71% from urban areas, and a mean age of 66 ± 13.3 years. Most patients were admitted for obstructive jaundice (49%), right upper quadrant abdominal pain (19%), nausea and loss of appetite in 13%, loss of weight (13%) and upper digestive obstruction in 6% of cases. All patients were evaluated with abdominal transparietal ultrasonography and double contrast, pancreatic protocol, Mutidetector Row Computed Tomography. The abdominal Magnetic Resonance Imaging was performed in 10 cases, upper gastrointestinal endoscopy in 9 cases, and Endoscopic Retrograde Cholangiopancreatography in 39 cases. According to the AJCC Cancer Staging 9% were into stage I, 47% into stage II, 40% into stage III and 4% into stage IV of the disease. The therapeutic approach was surgical for 44 patients and an endoscopic palliation with stent insertion in 4 cases. The surgical procedure was represented by Whipple pancreatoduodenectomy in 27 cases, pylorus preserving pancreatoduodenectomy in 15 cases and exploratory laparotomy in 2 cases. Early morbidity was represented by pancreatic leakage in 4 cases. Conclusions: There are clinical scenarios in which it is quite challenging to distinguish a primary ampullary adenocarcinoma based on a preoperative workup. Nevertheless, an aggressive approach should be performed, knowing the higher resectability rates and a five-year survival for these patients. Complete surgical resection should be performed in all medically fit patients, candidates for pancreatoduodenectomy, by a high volume, trained surgeon, able to offer a low morbidity and mortality. Carol Davila University Press 2013-09-15 2013-09-25 /pmc/articles/PMC3786484/ /pubmed/24146684 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Gaspar, B
Beuran, M
Paun, S
Ganescu, R
Hostiuc, S
Negoi, I
Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater
title Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater
title_full Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater
title_fullStr Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater
title_full_unstemmed Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater
title_short Current strategies in the therapeutic approach for adenocarcinoma of the ampulla of Vater
title_sort current strategies in the therapeutic approach for adenocarcinoma of the ampulla of vater
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786484/
https://www.ncbi.nlm.nih.gov/pubmed/24146684
work_keys_str_mv AT gasparb currentstrategiesinthetherapeuticapproachforadenocarcinomaoftheampullaofvater
AT beuranm currentstrategiesinthetherapeuticapproachforadenocarcinomaoftheampullaofvater
AT pauns currentstrategiesinthetherapeuticapproachforadenocarcinomaoftheampullaofvater
AT ganescur currentstrategiesinthetherapeuticapproachforadenocarcinomaoftheampullaofvater
AT hostiucs currentstrategiesinthetherapeuticapproachforadenocarcinomaoftheampullaofvater
AT negoii currentstrategiesinthetherapeuticapproachforadenocarcinomaoftheampullaofvater